Novel studies have reported more aggressive oral SCCs after EZH2-knockdown in a mouse model and discussed the tumor suppressor role of EZH2, concluding that EZH2-expression may differ even in the same cancer entity depending on the stage of disease. This evidence concerns the gene EZH2 and neoplasm.